Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
1.880
-0.120 (-6.00%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States.
Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Intensity Therapeutics, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Jun 30, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Lewis Bender |
Contact Details
Address: 1 Enterprise Drive, Suite 430 Shelton, Connecticut 06484-4779 United States | |
| Phone | 203 221 7381 |
| Website | intensitytherapeutics.com |
Stock Details
| Ticker Symbol | INTS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001567264 |
| CUSIP Number | 45812M104 |
| ISIN Number | US45828J1034 |
| Employer ID | 46-1488089 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Lewis H. Bender M.A., M.B.A., M.S. | Founder, President, Chief Executive Officer and Chairman of the Board |
| Joseph Talamo CPA, M.B.A. | Chief Financial Officer |
| John Wesolowski CPA, M.B.A. | Principal Accounting Officer and Controller |
| James M. Ahlers | Executive Vice President of Corporate Finance |
| Brian Schwartz M.D. | Executive Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 424B3 | Prospectus |
| Dec 19, 2024 | EFFECT | Notice of Effectiveness |
| Dec 13, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 5, 2024 | D | Notice of Exempt Offering of Securities |
| Nov 22, 2024 | 424B5 | Filing |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 424B5 | Filing |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Oct 23, 2024 | 8-K | Current Report |